No abstract available.
Family ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells ; Preservation, Biological

Hematologic Diseases ; Humans ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells

Mesenchymal stem cells(MSCs)is a kind of non hematopoietic stem cell from the mesoderm, which can self renew, proliferate and perform multilineage differentiation. Due to the characteristics of acquiring easily and low immunogenicity, it has become the main cell for myocardial infarction. In this article, the biology and the immunology of the MSCs is reviewed, the safety and the validity of the therapy on myocardial infarction with MSCs and the HGF/MSCs is introduced. And furthermore, it also explains the possible mechanism and the problems of how to improve the cardial function.
Cell Differentiation ; Hematopoietic Stem Cells ; Humans ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells ; Myocardial Infarction ; therapy

Composite biological and synthetic grafts with progenitor cells offer an alternative approach to auto- or allografts for fracture repair. This study was conducted to evaluate osteogenesis of autologous serum-derived albumin (ASA) scaffolds seeded with canine adipose tissue-derived mesenchymal stem cells (Ad-MSCs) in a canine segmental bone defect model. ASA scaffold was prepared with canine serum using cross-linking and freeze-drying procedures. Beta-tricalcium phosphate (beta-TCP) was mixed at the cross-linking stage. Ad-MSCs were seeded into the scaffold and incubated for one day before implantation. After 16 weeks, the grafts were harvested for histological analysis. The dogs were divided into five groups: control, ASA scaffolds with and without Ad-MSCs, and ASA scaffolds including beta-TCP with and without Ad-MSCs. ASA scaffolds with Ad-MSCs had a significantly larger area of increased opacity at the proximal and distal host cortex-implant interfaces in radiographs 16 weeks after implantation compared to the groups with beta-TCP (p < 0.05). Histomorphometric analysis showed that ASA scaffolds with Ad-MSCs had significantly greater new bone formation than other groups (p < 0.05). These results suggest that Ad-MSCs seeded into ASA scaffolds enhanced osteogenesis in the bone defect model, but that beta-TCP in the ASA scaffold might prevent penetration of the cells required for bone healing.
Allografts ; Animals ; Dogs ; Mesenchymal Stromal Cells* ; Osteogenesis* ; Stem Cells ; Transplants

Stem cell therapy using mesenchymal stem cells(MSCs) transplantation have been paid attention because of their powerful proliferation and pluripotent differentiating ability. Although umbilical cord blood (UCB) is well known to be a rich source of hematopoietic stem cells with practical and ethical advantages, the presence of mesenchymal stem cells (MSCs) in UCB has been controversial and it remains to be validated. In this study, we examine the presence of MSCs in UCB harvests and the prevalence of them is compared to that of endothelial progenitor cells. For this, CD34+ and CD34- cells were isolated and cultured under the endothelial cell growth medium and mesenchymal stem cell growth medium respectively. The present study showed that ESC-like cells could be isolated and expanded from preterm UCBs but were not acquired efficiently from full-terms. They expressed CD14-, CD34-, CD45-, CD29+, CD44+, CD105+ cell surface marker and could differentiate into adipogenic and osteogenic lineages. Our results suggest that MSCs are fewer in full-term UCB compared to endothelial progenitor cells.
Endothelial Cells ; Fetal Blood* ; Hematopoietic Stem Cells ; Humans* ; Mesenchymal Stromal Cells* ; Prevalence ; Stem Cells* ; Umbilical Cord

Stem cell therapy has been taken as a highly promising area of future medicine due to its potential for providing new therapeutic modalities for debilitating, incurable diseases. In addition, stem cell therapy holds promise for its great industrial value due to the rapid growth of the market size. Recently, various types of stem cells such as induced pluripotent stem cells are being developed based on the conceptual revolution with regard to cell fate decisions. However, so far, most stem cell therapies have been performed using tissue-specific adult stem cells. Nevertheless, except for a few cases of stem cells such as hematopoietic stem cells that can regenerate hematopoietic tissue, a large proportion of stem cells, especially mesenchymal stromal cells, primarily work through paracrine functioning. The short life span of the injected stem cells and their paracrine mode of action pose a limitation to the maximum therapeutic efficacy that can be achieved from the current stem cell therapy model, warranting further research and development to enhance their efficacy. Despite the fact that stem cell therapies largely remain in the research stage, the public has expectations of rapid results and even fanaticism, leading to unauthorized stem cell practices and medical tourism. Moreover, the temptation to expedite the industrialization of stem cell therapeutics by simplifying the authorization process could increase the risk of endangering the rights of patients. Thus, stem cell therapy can become a 'hope' when society can overcome the stem cell 'hype'.
Adult Stem Cells ; Hematopoietic Stem Cells ; Human Rights ; Humans ; Induced Pluripotent Stem Cells ; Medical Tourism ; Mesenchymal Stromal Cells ; Stem Cells

Bone marrow-derived mesenchymal stem cell (BMSC) transplantation is one ot the most popular therapeutic measures in severe acute pancreatitis (SAP). However, technical challenges and ethical concern have hindered its clinical application. Paracrine factor, as a new safe and easy handing therapeutic measure, can work comparably effective as BMSC transplantation in SAP therapy, but bio-safe risks could be greatly reduced. In this paper, we reviewed the therapeutic effect and potential mechanism of paracrine factors in the treatment of SAP. The injection of paracrine factors yielded from cultured cell suspension will be a new cell therapeutic measure for SAP.
Cells, Cultured ; Humans ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells ; chemistry ; Pancreatitis ; therapy

Mesenchymal stem cells (MSC) are the non-hematopoietic stem cells with a multi-differentiation potentials, which has a low immunogenicity and immune regulation ability. MSC immune regulation ability is particularly important, such as MSC can inhibit the activation and proliferation of T, B lymphocytes, NK cells and dendritic cells (DC). Meanwhile, MSC is able to reconstruct the human hematopoietic microenvironment, improving the successful rate of hematopoietic stem cell transplantation. Graft versus host disease (GVHD) is the main factor causing hematopoietic stem cell transplantation-related mortality. Based on the above mentioned properties, MSCs are used to treat autoimmune diseases and GVHD, recently. Therefore, deep exploration of the cellular immune mechanisms of MSC to treat GVHD is particularly important. This review focuses on progress of research related to treatment of GVHD by MSC immune mechanisms and briefly summarizes the status of the clinical studies.
Graft vs Host Disease ; immunology ; therapy ; Humans ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells ; immunology

OBJECTIVETo evaluate whether a combination therapy using allogeneic mesenchymal stem cell (MSC) transplantation and interleukin-1 receptor antagonist (IL-1Ra) chitosan nanoparticles is more robust than MSC transplantation alone for treating acute liver failure and to investigate the mechanisms of the improved therapeutic effect using a swine model system.

METHODSIL-1Ra-loaded nanoparticles were made of lactosylated chitosan-FITC using the electrostatic spray method and analyzed by enzyme-linked immunosorbent assay. The active live targeting of these nanopaticles were investigated by fluorescence microscope and flow cytometer(FCM). The combined therapy was given and the Detailed Steps as follows: Chinese experimental mini swine were given D-galactosamine to build models of acute liver failure. Thirty-four pigs were randomly divided into five groups. In the control group(A),the normal saline was injected into liver via portal veins after 24 h; in IL-1Ra group(B), IL-1Ra was injected via ear veins 6 h before normal saline; In the MSCs transplantation group (C), 8 * 107 MSCs were injected into liver via portal veins after 24 h; IL-1Ra together with MSCs transplantation group(D) and nanopaticles group(E) as follows: on the one hand, 8 * 107 MSCs were injected into liver via portal veins after 24 h, on the other hand, rhIL-1Ra in group C or IL-1Ra chitosan nanopaticles in group D was injected via ear veins respectively at 6 h before. Liver function, serum inflammation and pathological changes were measured. The fate of MSCs was also observed.

RESULTSThe profiles in vitro shown that there was a steady-state release after a fast linear release; The live targeting of the lactosylated chitosan-based nanoparticles was achieved by ligand-receptor specificity; The biochemical assay, the serum inflammation lever and pathological changes of the nanopaticles group were all greatly different from the other groups, the hepatocytes grow rate was significantly improved after 1 week; The liver engraftment was very low in group C and D with significantly higher numbers found in nanopaticles group, but the differentiation of MSCs after 2 weeks relatively rare; western blot showed that there was more HGF and VEGF secreted in nanopaticles group.

CONCLUSIONIL-lRa-loaded lactosylated chitosan-based nanopaticles have significant liver targeting abilities and slow release characteristics in PBS solution. The combined therapy showed great synergistic effects through suppression of liver inflammation and paracrine.

Mesenchymal stem cells (MSC) are multipotent cells able to differentiate into multiple lineages including cardiomyocytes and vascular endothelial cells under in vitro culture conditions. In vivo studies have shown that MSC can facilitate angiogenesis, and they localize to the site of ischemic injury which block or reverse the pathologic process. All the data suggest that MSC may be a promising strategy in the treatment of ischemic heart diseases. In recent years, more and more reports demonstrated that researchers have made enormous advances in this field. This review focuses on the angiogenesis and therapeutic applications of MSC derived from human bone marrow, including basic biological features of MSC, role of MSC in angiogenesis, preclinical study of MSC therapy in ischemic heart disease and prospect of MSC application in this disease.
Humans ; Mesenchymal Stem Cell Transplantation ; methods ; Mesenchymal Stromal Cells ; cytology ; Myocardial Ischemia ; surgery ; Neovascularization, Physiologic